All In Biotech

Drug Trial Radar · NCT06361875

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 908 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

908

Actual

Start

Apr 1, 2024

Primary completion

Jun 9, 2025

Study completion Jun 9, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Apr 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

Conditions

  • Influenza Immunization
  • Healthy Volunteers

Interventions

  • Quadrivalent Influenza mRNA Vaccine MRT5421Biological

    Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

  • Quadrivalent Influenza mRNA Vaccine MRT5424Biological

    Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

  • Quadrivalent Influenza mRNA Vaccine MRT5429Biological

    Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection

  • Quadrivalent Influenza Standard Dose VaccineBiological

    Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection

  • Quadrivalent Influenza High-Dose VaccineBiological

    Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection

  • Quadrivalent Recombinant Influenza VaccineBiological

    Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) After Vaccine AdministrationTime frame: Within 30 minutes after vaccine administration on Day 1
  2. Number of Participants With Solicited Injection Site Reactions After Vaccine AdministrationTime frame: Within 7 days after vaccine administration on Day 1
  3. Number of Participants With Solicited Systemic Reactions After Vaccine AdministrationTime frame: Within 7 days after vaccine administration on Day 1
  4. Number of Participants With Unsolicited Adverse Events After Vaccine AdministrationTime frame: Within 28 days after vaccine administration on Day 1
  5. Number of Participants With Medically Attended Adverse Events (MAAEs)Time frame: Within 180 days after vaccine administration on Day 1
  6. Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)Time frame: From the vaccine administration (Day 1) until 12 months after vaccine administration, approximately 366 days
  7. Number of Participants With Abnormal Biological Test ResultsTime frame: Within 8 days after vaccine administration on Day 1
  8. Geometric Mean of Hemagglutination Inhibition (HAI) Antibody (Ab) Titer at Day 1Time frame: Day 1
  9. Geometric Mean of Hemagglutination Inhibition Antibody Titer at Day 29Time frame: Day 29
  10. Percentage of Participants With Detectable Hemagglutination Inhibition Antibody Titer >=1:10 at Day 1Time frame: Day 1
  11. Percentage of Participants With Detectable Hemagglutination Inhibition Antibody Titer >=1:10 at Day 29Time frame: Day 29
  12. Geometric Mean Ratio of Hemagglutination Inhibition Antibody Titer at Day 29Time frame: Days 1 and 29
  13. Percentage of Participants With Seroconversion of Hemagglutination Inhibition Antibody Titer at Day 29Time frame: Day 29
  14. Percentage of Participants With Hemagglutination Inhibition Antibody Titer >=1:40 at Day 29Time frame: Day 29
  15. Percentage of Participants With >=2 and >=4 Fold Increase in Hemagglutination Inhibition Antibody Titer at Day 29Time frame: Days 1 and 29

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • California Research Foundation Site Number : 8400038

    San Diego, California

  • Indago Research and Health Center- Site Number : 8400032

    Hialeah, Florida

  • Cenexel Research Centers of America- Site Number : 8400037

    Hollywood, Florida

  • Brengle Family Medicine Site Number : 8400045

    Indianapolis, Indiana

  • AMR Lexington- Site Number : 8400042

    Lexington, Kentucky

  • Velocity Clinical Research- New Orleans Site Number : 8400053

    New Orleans, Louisiana

  • The Alliance for Multispecialty Research - KCM, LLC- Site Number : 8400034

    Kansas City, Missouri

  • Velocity Clinical Research Norfolk- Site Number : 8400046

    Norfolk, Nebraska

  • AMR Knoxville- Site Number : 8400043

    Knoxville, Tennessee

  • Clinical Trials of Texas, Inc. - PPDS- Site Number : 8400029

    San Antonio, Texas

  • Cenexel JBR- Site Number : 8400051

    Salt Lake City, Utah

  • Investigational Site Number : 3400001

    San Pedro Sula, Honduras

  • Investigational Site Number : 6300002

    Barrio Sabana, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.